Sobi’s Anakinra (Kineret) Prioritized for Review in China for FMF Treatment
The Center for Drug Evaluation (CDE) website indicates that Swedish Orphan Biovitrum AB’s (Sobi; BMV:...
Drug
Arctic Vision Enrolls First Patient in ARVN003 Phase III Trial for Presbyopia
China-based ophthalmic therapies developer Arctic Vision announced the first patient enrollment in a Phase III...
JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma
China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...
Brii Biosciences Exercises Option for VIR-3434 in Greater China
China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...
Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis
China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...
Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...
InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production
Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...
Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...
Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...
Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide
China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...
Bio-Thera Solutions’ BAT8010 Receives NMPA Approval for Solid Tumor Clinical Trials
Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced that it has received approval from the National Medical...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...
BeiGene’s Tislelizumab Shows Survival Benefit in Esophageal Cancer Study
BeiGene (NASDAQ: BGNE) has released the latest results of the global Phase III RATIONALE 306...
Huadong Medicine’s Biosimilar Ozempic (Semaglutide) Wins NMPA Clinical Trial Approval
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that a clinical trial filing for its...
Jixing Pharmaceuticals Enrolls First Patient in Etripamil Phase III Study for PSVT
China-based Ji Xing Pharmaceuticals Ltd (Jixing) announced the first patient enrollment in a Phase III...
Takeda’s Obizur Prioritized for Review in Acquired Hemophilia A Treatment
The Center for Drug Evaluation (CDE) website indicates that Takeda Pharmaceutical Co., Ltd’s Obizur (susoctocog...
Allist Pharmaceuticals’ Furmonertinib Receives NMPA Approval for First-Line NSCLC Treatment
Shanghai-based Allist Pharmaceuticals Inc. (SHA: 688578) announced that it has received another indication approval from...
Ascentage Pharma’s APG-5918 Receives FDA Approval for First-in-Human Study
Suzhou-based Ascentage Pharma (HKG: 6855) announced that it has received approval from the US Food...
Ascletis Pharma Doses First Patient in China’s Phase II Trial for HIV-1 Treatment with ASC22
China-based Ascletis Pharma Inc. (HKG: 1672) announced the dosing of the first patient in its...
Jixing Pharmaceuticals’ Aficamten Receives CDE Approval for Phase III HCM Study
China-based Ji Xing Pharmaceuticals announced receiving approval from the Center for Drug Evaluation (CDE) to...